Bioavailability Study of PF-06651600 Formulations in Healthy Participants
Status:
Completed
Trial end date:
2019-10-11
Target enrollment:
Participant gender:
Summary
The study will be conducted as a Phase 1, open-label, single dose, randomized, 4-period,
cross over design in a single cohort of approximately 12 healthy male or female participants
at a single center. Participants will be randomized into 1 of 4 sequences of treatment.